# US 2018/0021394 A1 · Asteriscus graveolens extracts and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021394 A1
- Document ID: US20180021394A1
- Status: Published application
- Kind: A1
- Application number: 15/547,385
- Filed: 2016-02-01
- Published: 2018-01-25
- Earliest claimed: 2015-02-02
- Assignees: I.B.R. Israeli Biotechnology Research Ltd.
- Applicants: I.B.R. Israeli Biotechnology Research Ltd.
- Inventors: Ofir Ramot; Fabien Havas; Eyal Kalo; Liki Von Oppen-Bezalel; Raffi Arnon; Olga Ben-Chitrit; Inon Perry
- Web page: https://patentgrep.com/patent/US20180021394A1

## CPC

- A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K 8/9789: Magnoliopsida [dicotyledons]
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 11/00: Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- A61Q 17/00: Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/08: Anti-ageing preparations
- A61K 2236/00: Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K 2236/331: using water, e.g. cold water, infusion, tea, steam distillation or decoction
- A61K 2236/333: using mixed solvents, e.g. 70% EtOH
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates to extracts derived from plants and/or fractions thereof, compositions comprising same and use thereof in protecting tissues from damages caused by exogenous toxins. In particular, the present invention relates to polar extract and/or fraction thereof derived from Asteriscus graveolens, compositions comprising same and use thereof in protecting tissues comprising epithelial cell from the deleterious effect of exogenous toxins, particularly toxins originating from environmental pollution.

## Claims

### Claim 1

A method for protecting a tissue comprising epithelial cells from the deleterious effect of at least one pollutant comprising:
topically administering to a skin of a subject in need thereof a composition comprising an effective dose of a polar solvent extract derived from Asteriscus graveolens plant, a fraction thereof or any combination of a polar solvent extract derived from Asteriscus graveolens plant and a fraction thereof, so as to result in protecting the tissue from the at least one pollutant.

### Claim 2 (depends on 1)

The method of claim 1, wherein the effective dose is from 0.1% to 10% w/w relative to the total weight of the composition.

### Claim 3 (depends on 1)

The method of claim 1, wherein the at least one pollutant originates from at least one of combustion gas, industrial pollutions and smoke.

### Claim 4

(canceled)

### Claim 5 (depends on 3)

The method of claim 3, wherein the smoke is tobacco smoke.

### Claim 6 (depends on 1)

The method of claim 1 wherein the test, to determine whether the composition results in protecting the tissue from the at least one pollutant, is the following: the epithelial cells of a subject were cultured in culture medium for 24 hours. The medium was then removed and replaced by assay medium containing the composition; After 24 hours of pre-incubation, the
medium was replaced by cigarette smoke-intoxicated medium containing the composition; The experiment was performed using several concentrations of cigarette smoke-intoxicated assay medium (8 concentrations ranging from 5% to 90% of intoxicated medium); Cells were incubated with the smoke-intoxicated medium for 24 hours;
Cell viability after exposure to the smoke-tainted medium was measured by Photometry; ((3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide), a pale yellow substrate, is cleaved by succinate dehydrogenase present in living cells to yield a dark blue water-insoluble formazan salt;
The transformation is proportional to the enzyme activity; After cell dissociation and formazan crystal solubilization using DMSO, the topical density (OD) of the extract at 540 nm, proportional to the number of living cells and their metabolic activity, was recorded with a microplate reader (VERSAmax, Molecular Devices); The cytotoxicity of increasing concentrations of smoke-tainted medium and the IC50 of the smoke-tainted medium is determined (percentage of smoke tainted medium resulting in 50% inhibition of cell viability);
an increase in the ICso (representing an increase in the dose of tainted medium necessary to have a significant toxic effect, i.e. a decrease in said medium's toxicity) represents a protective effect of the composition.

### Claim at position 7

-10. (canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein protecting the skin from the deleterious effect of the at least one pollutant results in at least one outcome selected from the group consisting of increased skin cell viability, improved skin appearance, reduced premature skin aging and any combination thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein improved skin appearance and/or reduced premature skin aging comprises reduction in the appearance of at least one of wrinkles, brown spots and red spots of the skin.

### Claim at position 10

-16. (canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the pollutant comes in contact with the tissue comprising epithelial cells in its isolated form.

### Claim at position 12

-22. (canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein the polar solvent is water.

### Claim 24 (depends on 1)

The method of claim 1, wherein the polar solvent comprises water and at least one additional polar solvent.

### Claim 25 (depends on 24)

The method of claim 24, wherein the at least one additional polar solvent is selected from the group consisting of glycerin, ethanol, propylene glycol, butylene glycol, methanol, and acetone.

### Claim 26 (depends on 25)

The method of claim 25, wherein the polar solvent comprises water and glycerin.

### Claim 27 (depends on 26)

The method of claim 26, wherein the polar solvent extract and/or fraction thereof is in a form of a solution comprising 40 to 60% (w/w) glycerin.

### Claim 28 (depends on 1)

The method of claim 1, wherein the polar solvent extract or a fraction thereof is essentially devoid of essential oils.

### Claim at position 19

-38. (canceled)

### Claim 39 (depends on 1)

The composition of claim 1, further comprising an additional active agent selected from the group consisting of an anti-oxidant, a chelator, a cleansing agent, a skin protectant, a sunscreen, a skin lightening agent, an anti-wrinkling agent, an anti-inflammatory agent, an anti-aging agent, and any combination thereof.

### Claim 40 (depends on 1)

The composition of claim 1, said composition is a cosmetic composition formulated for topical administration to the skin.

### Claim at position 22

-48. (canceled)